GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (OTCPK:MDBBF) » Definitions » EPS without NRI

Medlab Clinical (Medlab Clinical) EPS without NRI : $-1.15 (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Medlab Clinical EPS without NRI?

Medlab Clinical's earnings per share without non-recurring items for the six months ended in Dec. 2023 was $-0.58. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.15.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 30.70% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -42.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Medlab Clinical's EPS without NRI or its related term are showing as below:

MDBBF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -355.2   Med: -22.1   Max: 30.7
Current: 30.7

During the past 8 years, Medlab Clinical's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 30.70% per year. The lowest was -355.20% per year. And the median was -22.10% per year.

MDBBF's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.5 vs MDBBF: 30.70

Medlab Clinical's EPS (Diluted) for the six months ended in Dec. 2023 was $-0.58. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.15.

Medlab Clinical's EPS (Basic) for the six months ended in Dec. 2023 was $-0.58. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.15.


Medlab Clinical EPS without NRI Historical Data

The historical data trend for Medlab Clinical's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlab Clinical EPS without NRI Chart

Medlab Clinical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EPS without NRI
Get a 7-Day Free Trial -4.03 -6.15 -4.79 -384.75 -1.99

Medlab Clinical Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.32 -1.27 -1.44 -0.57 -0.58

Competitive Comparison of Medlab Clinical's EPS without NRI

For the Biotechnology subindustry, Medlab Clinical's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medlab Clinical's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's PE Ratio without NRI falls into.



Medlab Clinical EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-1.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medlab Clinical  (OTCPK:MDBBF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Medlab Clinical EPS without NRI Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Medlab Clinical (Medlab Clinical) Business Description

Traded in Other Exchanges
N/A
Address
11 Lord Street, Unit 5, Botany, NSW, AUS, 2019
Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.

Medlab Clinical (Medlab Clinical) Headlines